Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1793 results
October 2019
-
Key ReleaseNovartis verzeichnet ein weiteres starkes Quartal mit zweistelligem Umsatz-wachstum und höherer Kerngewinnmarge1; Umsatz- und Gewinnerwartung für 2019 angehoben; US-Einführung von BeovuDer Nettoumsatz der fortzuführenden Geschäftsbereiche2 steigt aufgrund folgender Beiträge um 13% (kWk1, +10% USD): Cosentyx erzielt einen Umsatz von USD 937 Millionen (+27% kWk)…
-
Key ReleaseNovartis, encore un fort trimestre: croissance à deux chiffres des ventes et expansion de la marge core1; hausse des prévisions de chiffre d’affaires et de résultat en 2019; Beovu lancé aux USAChiffre d’affaires net des activités poursuivies2 en hausse de 13% (tcc1, +10% USD) soutenu par: Cosentyx: USD 937 millions (+27% tcc), avec une forte demande dans toutes les indications et…
-
Media ReleaseNovartis announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase III study of acute graft-versus-host diseaseREACH2 trial results confirm Jakavi significantly improves overall response rate (ORR) at 28 days vs. best available therapy in steroid-refractory acute graft-versus-host disease (GvHD)[1] GvHD…
-
Featured NewsPride @ Novartis 2019
As a company, we stand up for greater inclusion of LGBTI people because when each of us feels included, we all benefit.
-
Media ReleaseNovartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitisNew two-year data compare the effects of Cosentyx (secukinumab) treatment in psoriatic arthritis patients with and without enthesitis, a manifestation described in 30-50% of patients [1] Results…
-
Featured NewsNovartis and Microsoft announce collaboration to transform medicine with artificial intelligence
On Tuesday September 1, 2019 Novartis and Microsoft announced a multiyear alliance which will leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized. Novartis is also establishing an AI Innovation Lab to empower associates to use AI across our business.
-
Featured NewsWorld Sight Day 2019
-
Media ReleaseNovartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practiceData from five real-world evidence (RWE) and observational studies being conducted in North America, Latin America and Europe provide extensive cumulative insights for Cosentyx (secukinumab) clinical…
-
Lessons from a blind chef
Christine Hà lost her vision at a young age – and went on to become an award-winning chef.
-
Media ReleaseNovartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mgResults from a Phase IIb dose-finding study show an average complete response rate of 42% for doses 240 mg and 72 mg ligelizumab at Week 12 compared with 26% for those taking 300 mg Xolair’s dose (…
-
Key ReleaseNovartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs afliberceptIn two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
-
Oncology Careers: Life Changing Purpose
Pagination
- ‹ Previous page
- 1
- …
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- …
- 150
- › Next page